4.5 Article

Risk Factors, Neuroanatomical Correlates, and Outcome of Neuropsychiatric Symptoms in Alzheimer's Disease

期刊

JOURNAL OF ALZHEIMERS DISEASE
卷 60, 期 2, 页码 483-493

出版社

IOS PRESS
DOI: 10.3233/JAD-160767

关键词

Alzheimer's disease; Alzheimer's Disease Neuroimaging Initiative; apathy; depression; neuropsychiatric inventory; neuropsychiatric symptoms; psychosis

资金

  1. NIH [P30 AG010129, K01 AG030514]
  2. Dana Foundation
  3. Laval University, Quebec City, Canada
  4. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant) [U01 AG024904]
  5. National Institute on Aging
  6. National Institute of Biomedical Imaging and Bioengineering
  7. Alzheimer's Association
  8. Alzheimer's Drug Discovery Foundation
  9. BioClinica, Inc.
  10. Biogen Idec Inc.
  11. Bristol-Myers Squibb Company
  12. Eisai Inc.
  13. Elan Pharmaceuticals, Inc.
  14. Eli Lilly and Company
  15. F. Hoffmann-La Roche Ltd
  16. affiliated company Genentech, Inc.
  17. GE Healthcare
  18. Innogenetics, N.V.
  19. IXICO Ltd.
  20. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  21. Johnson & Johnson Pharmaceutical Research & Development LLC.
  22. Medpace, Inc.
  23. Merck Co., Inc.
  24. Meso Scale Diagnostics, LLC.
  25. NeuroRx Research
  26. Novartis Pharmaceuticals Corporation
  27. Pfizer Inc.
  28. Piramal Imaging
  29. Servier
  30. Synarc Inc.
  31. Takeda Pharmaceutical Company
  32. Canadian Institutes of Health Research
  33. [R01-AG029411]
  34. [R21-AG029840]
  35. [P50-AG05134]
  36. [P50-AG05681]
  37. [P01-AG003991]
  38. [U24-RR021382]
  39. [R01-MH56584]
  40. [R01-AG030311]
  41. [DP1OD003312]

向作者/读者索取更多资源

Background: An integrative model of neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) is lacking. Objective: In this study, we investigated the risk factors, anatomy, biology, and outcomes of NPS in AD. Methods: 181 subjects were included from the Alzheimer's Disease Neuroimaging Study (ADNI). NPS were assessed with the Neuropsychiatric Inventory Questionnaire at baseline and 6 months. NPI > 3 was used as a threshold for NPS positivity. Three NPS courses were characterized: 1) minimal/absent (negative at 0 and 6 months, n = 77); 2) fluctuating (positive only at one time point, n = 53); 3) persistent (positive at both time points, n = 51). We examined the association between NPS course and family history of dementia, personal history of psychiatric disorders, cerebrospinal fluid biomarkers, atrophy patterns, as well as longitudinal cognitive and functional measures at 12 and 24 months (MMSE, CDR-SOB, FAQ). Results: AD subjects with absent, fluctuating, or persistent NPS had similar CSF amyloid-beta and tau levels. AD subjects with minimal/absent NPS had less personal history of psychiatric disorders (35%) than those with fluctuating (57%; p = 0.015) or persistent NPS (47%, not significant). At 24 months, AD subjects with persistent NPS had worse cognitive (MMSE; p = 0.05) and functional (CDR-SOB; p = 0.016) outcomes. Dorsolateral prefrontal atrophy was seen in persistent NPS, but not in fluctuating NPS. Conclusions: Our results suggest that individuals with personal history of psychiatric disorders might be more vulnerable to develop NPS throughout the course of AD. The worst cognitive and functional outcomes associated with NPS in AD underscores the importance of monitoring NPS early in the disease course.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据